Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436539 | 0.86 | THRB (0.39) | KMT2ASMN1; SMN2ALDH1A1PRSS1MAPT | |
| SCHEMBL19451511 | 0.85 | PRSS1 (0.36) | HPGDKMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL19451492 | 0.84 | PRSS1 (0.51) | HPGDKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL19436516 | 0.82 | GPR119 (0.49) | SCN9A | |
| SCHEMBL25812585 | 0.82 | ALDH1A1 (0.39) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL28308732 | 0.81 | PARP15 (0.46) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL30803074 | 0.81 | PARP15 (0.46) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL21156963 | 0.81 | LMNA (0.40) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL22121409 | 0.81 | PRSS1 (0.48) | KMT2ASMN1; SMN2ALDH1A1PRSS1MAPT | |
| SCHEMBL22121068 | 0.80 | KMT2A (0.42) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | HPGD 4329/4885KMT2A 1428/4885SMN1; SMN2 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.